

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waiver under Section 712(c)(2)(B) and 18 U.S.C. §208(b)(3)

S. Gail Eckhardt, M.D.

Committees: Oncologic Drugs Advisory Committees

Meeting Date: December 5, 2007

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to discussions of supplemental BLA 125085/91, Avastin (bevacizumab), Genetech, Inc., proposed indication, in combination with paclitaxel, for the treatment of patients who have not received chemotherapy for their locally recurrent or metastatic, HER2 negative breast cancer, I am eligible to receive a waiver under Section 712(c)(2)(B) and 18 U.S.C. §208 (b)(3).

Type of Interest	Nature	Magnitude
Unrelated consulting	Sponsor	Less than \$10,001 per year

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued by reading the statement into the record at the time of the meeting. I understand that without public disclosure of this interest the waiver is not valid.

/S/
Signature of SGE

10/20/07
Date